Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general’s ...

We are in an era of unprecedented medical innovation. Scientists are making remarkable progress to diagnose and treat ...

NORTHAMPTON, MA / ACCESS Newswire / May 7, 2025 / By Catharine Grimes, President of the Bristol Myers Squibb FoundationWe are in an era of unprecedented medical innovation. Scientists are making remar ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a subcutaneous injectable version of the cancer drug nivolumab (Opdivo, Bristol Myers Squibb). NHS England said it would ...

Coming through for her team with a big game in a one-game playoff, Bishop's Alida Garcia has been voted the Driscoll Children's Hospital Caller-Times High School Athlete of the Week for April 21-26.

The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) in the US has announced its new Children's Same Day Services centre, aimed at providing ...

Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Call Transcript April 24, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.8, expectations were $1.49.

Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...

Bristol Myers Squibb Co. raised its sales and profit forecasts for the year on better-than-expected sales of older drugs and a favorable impact from the weaker dollar. The first quarter saw strong ...

Bristol-Myers Squibb Company reported stronger-than-expected financial results for the first quarter of 2025, with earnings per share (EPS) of $1.80, surpassing analysts’ forecasts of $1.52.